Pharmacoepidemiology as a focus for clinical epidemiology in developing countries.

H. Guess,C. Goldsmith,D. Henry,B. Strom

DOI: https://doi.org/10.1016/0895-4356(91)90120-X

IF: 7.407

Journal of Clinical Epidemiology

Abstract:

What problem does this paper attempt to address?

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021

Carla L DeSisto,Bailey Wallace,Regina M Simeone,Kara Polen,Jean Y Ko,Dana Meaney-Delman,Sascha R Ellington

DOI: https://doi.org/10.15585/mmwr.mm7047e1

2021-11-26

Abstract:Pregnant women are at increased risk for severe COVID-19-related illness, and COVID-19 is associated with an increased risk for adverse pregnancy outcomes and maternal and neonatal complications (1-3). To date, studies assessing whether COVID-19 during pregnancy is associated with increased risk for stillbirth have yielded mixed results (2-4). Since the B.1.617.2 (Delta) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant,* there have been anecdotal reports of increasing rates of stillbirths in women with COVID-19.† CDC used the Premier Healthcare Database Special COVID-19 Release (PHD-SR), a large hospital-based administrative database,§ to assess whether a maternal COVID-19 diagnosis documented at delivery hospitalization was associated with stillbirth during March 2020-September 2021 as well as before and during the period of Delta variant predominance in the United States (March 2020-June 2021 and July-September 2021, respectively). Among 1,249,634 deliveries during March 2020-September 2021, stillbirths were rare (8,154; 0.65%): 273 (1.26%) occurred among 21,653 deliveries to women with COVID-19 documented at the delivery hospitalization, and 7,881 (0.64%) occurred among 1,227,981 deliveries without COVID-19. The adjusted risk for stillbirth was higher in deliveries with COVID-19 compared with deliveries without COVID-19 during March 2020-September 2021 (adjusted relative risk [aRR] = 1.90; 95% CI = 1.69-2.15), including during the pre-Delta (aRR = 1.47; 95% CI = 1.27-1.71) and Delta periods (aRR = 4.04; 95% CI = 3.28-4.97). COVID-19 documented at delivery was associated with increased risk for stillbirth, with a stronger association during the period of Delta variant predominance. Implementing evidence-based COVID-19 prevention strategies, including vaccination before or during pregnancy, is critical to reducing the impact of COVID-19 on stillbirths.
Mucosal Allergic Sensitization to Cockroach Allergens Is Dependent on Proteinase Activity and Proteinase-Activated Receptor-2 Activation

N. Arizmendi,M. Abel,K. Mihara,C. Davidson,D. Polley,A. Nadeem,T. E. El Mays,B. Gilmore,B. Walker,J. Gordon,M. Hollenberg,H. Vliagoftis

DOI: https://doi.org/10.4049/jimmunol.0903812

2011-03-01

Abstract:We have shown that proteinase-activated receptor-2 (PAR2) activation in the airways leads to allergic sensitization to concomitantly inhaled Ags, thus implicating PAR2 in the pathogenesis of asthma. Many aeroallergens with proteinase activity activate PAR2. To study the role of PAR2 in allergic sensitization to aeroallergens, we developed a murine model of mucosal sensitization to cockroach proteins. We hypothesized that PAR2 activation in the airways by natural allergens with serine proteinase activity plays an important role in allergic sensitization. Cockroach extract (CE) was administered to BALB/c mice intranasally on five consecutive days (sensitization phase) and a week later for four more days (challenge phase). Airway hyperresponsiveness (AHR) and allergic airway inflammation were assessed after the last challenge. To study the role of PAR2, mice were exposed intranasally to a receptor-blocking anti-PAR2 Ab before each administration of CE during the sensitization phase. Mucosal exposure to CE induced eosinophilic airway inflammation, AHR, and cockroach-specific IgG1. Heat-inactivated or soybean trypsin inhibitor-treated CE failed to induce these effects, indicating that proteinase activity plays an important role. The use of an anti-PAR2 blocking Ab during the sensitization phase completely inhibited airway inflammation and also decreased AHR and the production of cockroach-specific IgG1. PAR2 activation by CE acts as an adjuvant for allergic sensitization even in the absence of functional TLR4. We conclude that CE induces PAR2-dependent allergic airway sensitization in a mouse model of allergic airway inflammation. PAR2 activation may be a general mechanism used by aeroallergens to induce allergic sensitization.
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

José Villar,Shabina Ariff,Robert B. Gunier,Ramachandran Thiruvengadam,Stephen Rauch,Alexey Kholin,Paola Roggero,Federico Prefumo,Marynéa Silva do Vale,Jorge Arturo Cardona-Perez,Nerea Maiz,Irene Cetin,Valeria Savasi,Philippe Deruelle,Sarah Rae Easter,Joanna Sichitiu,Constanza P. Soto Conti,Ernawati Ernawati,Mohak Mhatre,Jagjit Singh Teji,Becky Liu,Carola Capelli,Manuela Oberto,Laura Salazar,Michael G. Gravett,Paolo Ivo Cavoretto,Vincent Bizor Nachinab,Hadiza Galadanci,Daniel Oros,Adejumoke Idowu Ayede,Loïc Sentilhes,Babagana Bako,Mónica Savorani,Hellas Cena,Perla K. García-May,Saturday Etuk,Roberto Casale,Sherief Abd-Elsalam,Satoru Ikenoue,Muhammad Baffah Aminu,Carmen Vecciarelli,Eduardo A. Duro,Mustapha Ado Usman,Yetunde John-Akinola,Ricardo Nieto,Enrico Ferrazzi,Zulfiqar A. Bhutta,Ana Langer,Stephen H. Kennedy,Aris T. Papageorghiou

DOI: https://doi.org/10.1001/jamapediatrics.2021.1050

2021-08-01

JAMA Pediatrics

Abstract:ImportanceDetailed information about the association of COVID-19 with outcomes in pregnant individuals compared with not-infected pregnant individuals is much needed.ObjectiveTo evaluate the risks associated with COVID-19 in pregnancy on maternal and neonatal outcomes compared with not-infected, concomitant pregnant individuals.Design, Setting, and ParticipantsIn this cohort study that took place from March to October 2020, involving 43 institutions in 18 countries, 2 unmatched, consecutive, not-infected women were concomitantly enrolled immediately after each infected woman was identified, at any stage of pregnancy or delivery, and at the same level of care to minimize bias. Women and neonates were followed up until hospital discharge.ExposuresCOVID-19 in pregnancy determined by laboratory confirmation of COVID-19 and/or radiological pulmonary findings or 2 or more predefined COVID-19 symptoms.Main Outcomes and MeasuresThe primary outcome measures were indices of (maternal and severe neonatal/perinatal) morbidity and mortality; the individual components of these indices were secondary outcomes. Models for these outcomes were adjusted for country, month entering study, maternal age, and history of morbidity.ResultsA total of 706 pregnant women with COVID-19 diagnosis and 1424 pregnant women without COVID-19 diagnosis were enrolled, all with broadly similar demographic characteristics (mean [SD] age, 30.2 [6.1] years). Overweight early in pregnancy occurred in 323 women (48.6%) with COVID-19 diagnosis and 554 women (40.2%) without. Women with COVID-19 diagnosis were at higher risk for preeclampsia/eclampsia (relative risk [RR], 1.76; 95% CI, 1.27-2.43), severe infections (RR, 3.38; 95% CI, 1.63-7.01), intensive care unit admission (RR, 5.04; 95% CI, 3.13-8.10), maternal mortality (RR, 22.3; 95% CI, 2.88-172), preterm birth (RR, 1.59; 95% CI, 1.30-1.94), medically indicated preterm birth (RR, 1.97; 95% CI, 1.56-2.51), severe neonatal morbidity index (RR, 2.66; 95% CI, 1.69-4.18), and severe perinatal morbidity and mortality index (RR, 2.14; 95% CI, 1.66-2.75). Fever and shortness of breath for any duration was associated with increased risk of severe maternal complications (RR, 2.56; 95% CI, 1.92-3.40) and neonatal complications (RR, 4.97; 95% CI, 2.11-11.69). Asymptomatic women with COVID-19 diagnosis remained at higher risk only for maternal morbidity (RR, 1.24; 95% CI, 1.00-1.54) and preeclampsia (RR, 1.63; 95% CI, 1.01-2.63). Among women who tested positive (98.1% by real-time polymerase chain reaction), 54 (13%) of their neonates tested positive. Cesarean delivery (RR, 2.15; 95% CI, 1.18-3.91) but not breastfeeding (RR, 1.10; 95% CI, 0.66-1.85) was associated with increased risk for neonatal test positivity.Conclusions and RelevanceIn this multinational cohort study, COVID-19 in pregnancy was associated with consistent and substantial increases in severe maternal morbidity and mortality and neonatal complications when pregnant women with and without COVID-19 diagnosis were compared. The findings should alert pregnant individuals and clinicians to implement strictly all the recommended COVID-19 preventive measures.

medicine, general & internal
An Analysis of the CRONOS Register Study

Antonella Iannaccone,Alexandra Gellhaus,Beatrix Reisch,Mark Dzietko,Boerge Schmidt,Laven Mavarani,Katrina Kraft,Kristin Andresen,Rainer Kimmig,Ulrich Pecks,Ekkehard Schleußner

DOI: https://doi.org/10.3390/jcm13061522

IF: 3.9

2024-03-08

Journal of Clinical Medicine

Abstract:Background: The risk of preterm birth (PTB) and stillbirth increases after a SARS-CoV-2 infection during gestation. We aimed to estimate the risk depending on gestational age at infection (early <28 + 0 and late ≥28 weeks of gestation, WoG), virus variants, severity of infection, and vaccination. Methods: PTB was divided into early PTB (<32 + 0) and late PTB (32 + 0–36 + 6 WoG). The prospective register COVID-19 Related Obstetrics and Neonatal Outcome Study (CRONOS) included 8032 pregnant women with a confirmed SARS-CoV-2 infection from 3 April 2020 to 31 December 2022, in Germany and Austria. Results: Stillbirth and early preterm births rates were higher during the Alpha (1.56% and 3.13%) and Delta (1.56% and 3.44%) waves than during the Omicron wave (0.53% and 1.39%). Early SARS-CoV-2 infection increased the risk for stillbirth (aRR 5.76, 95% CI 3.07–10.83) and early PTB before 32 + 0 (aRR, 6.07, 95% CI 3.65–10.09). Hospital admission increased the risks further, especially in the case of ICU admission. Vaccination against SARS-CoV-2 significantly reduced the risk of stillbirth (aRR 0.32, 95% CI 0.16–0.83). Conclusions: This multicentric prospective study shows an increased risk of stillbirth and preterm birth after infection early in pregnancy and therefore the importance of obstetrical surveillance thereafter. Vaccination offers effective protection.

medicine, general & internal
Rheumatic Disease Clinics of North America. Vitamin D. Preface.

S. Epstein

DOI: https://doi.org/10.1016/j.rdc.2012.03.002

IF: 2.032

2012-02-01

Rheumatic Disease Clinics of North America

Abstract:
Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China

Rong Yang,Hui Mei,Tongzhang Zheng,Qiang Fu,Yiming Zhang,Stephen Buka,Xinan Yao,Zezhong Tang,Xichi Zhang,Lin Qiu,Yaqi Zhang,Jieqiong Zhou,Jiangxia Cao,Youjie Wang,Aifen Zhou

DOI: https://doi.org/10.1186/s12916-020-01798-1

IF: 9.3

2020-10-19

BMC Medicine

Abstract:Abstract Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. However, little is known about the association between pregnant women with COVID-19 and the risk of adverse birth outcomes. Method We conducted a retrospective cohort study based on the Maternal and Child Health Information System (MCHIMS) of Wuhan, China. All pregnant women with singleton live birth recorded by the system between January 13 and March 18, 2020, were included. The adverse birth outcomes were preterm birth, low birth weight, neonatal asphyxia, premature rupture of membrane (PROM), and cesarean section delivery. Multivariate logistic regression was used to evaluate the associations between maternal COVID-19 diagnosis and adverse birth outcomes. Results Out of 11,078 pregnant women, 65 were confirmed with coronavirus disease 2019 (COVID-19). No deaths occurred from these confirmed cases or their newborns. Compared to pregnant women without COVID-19, pregnant women with a confirmed COVID-19 diagnosis had an increased risk of preterm birth (OR 3.34, 95% CI 1.60–7.00) and cesarean section (OR 3.63, 95% CI 1.95–6.76). There was no statistical difference in low birth weight, neonatal asphyxia, and PROM between the mothers with and without COVID-19. Among these newborns that were born to mothers with confirmed COVID-19, none was tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive or had abnormal CT results. Only one had diarrhea and three had a fever. Conclusions This population-based cohort study suggests that COVID-19 during the later pregnancy is associated with an increased risk of adverse birth outcomes, including iatrogenic preterm birth and cesarean section delivery. Our data provide little evidence for maternal-fetal vertical transmission of SARS-CoV-2. It is important to monitor the long-term health effects of SARS-CoV-2 infection on pregnant women and their children.

medicine, general & internal
Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review

Ozlem Turan,Amir Hakim,Pradip Dashraath,Wong Jing Lin Jeslyn,Alison Wright,Rezan Abdul-Kadir

DOI: https://doi.org/10.1002/ijgo.13329

Abstract:Background: Pregnant women represent a potentially high-risk population in the COVID-19 pandemic. Objective: To summarize clinical characteristics and outcomes among pregnant women hospitalized with COVID-19. Search strategy: Relevant databases were searched up until May 29, 2020. Selection criteria: Case series/reports of hospitalized pregnant women with laboratory-confirmed COVID-19. Data collection and analysis: PRISMA guidelines were followed. Methodologic quality was assessed via NIH assessment tools. Main results: Overall, 63 observational studies of 637 women (84.6% in third trimester) with laboratory-confirmed SARS-CoV-2 infection were included. Most (76.5%) women experienced mild disease. Maternal fatality, stillbirth, and neonatal fatality rates were 1.6%, 1.4%, and 1.0%, respectively. Older age, obesity, diabetes mellitus, and raised serum D-dimer and interleukin-6 were predictive of poor outcomes. Overall, 33.7% of live births were preterm, of which half were iatrogenic among women with mild COVID-19 and no complications. Most women underwent cesarean despite lacking a clear indication. Eight (2.0%) neonates had positive nasopharyngeal swabs after delivery and developed chest infection within 48 hours. Conclusions: Advanced gestation, maternal age, obesity, diabetes mellitus, and a combination of elevated D-dimer and interleukin-6 levels are predictive of poor pregnancy outcomes in COVID-19. The rate of iatrogenic preterm birth and cesarean delivery is high; vertical transmission may be possible but has not been proved.
Is Termination of Early Pregnancy Indicated in Women with COVID-19?

Yan-Ting Wu,Cheng Li,Chen-Jie Zhang,He-Feng Huang

DOI: https://doi.org/10.1016/j.ejogrb.2020.05.037

IF: 2.831

2020-01-01

European Journal of Obstetrics & Gynecology and Reproductive Biology

Abstract:By May 11, 2020, more than 84,430 confirmed cases and 4 suspected cases infected with 2019 novel coronavirus disease (COVID-19) have been reported in China. Besides the human-to-human transmission via respiratory droplet, vertical transmission has been concerned and not determined since one case of a mother and neonate was laboratory-confirmed with COVID-19. We studied 13 COVID-19 infected pregnant women from Renmin Hospital of Wuhan University, Wuhan, Hubei province, China and published online [[1]Wu Y. Liu C. Dong L. et al.Coronavirus disease 2019 among pregnant Chinese women: case series data on the safety of vaginal birth and breastfeeding.BJOG. 2020; ([Epub ahead of print])https://doi.org/10.1111/1471-0528.16276Crossref Scopus (139) Google Scholar]. One woman in that study experienced the biochemical pregnancy. It is unclear whether the biochemical pregnancy was associated with maternal infection, and therefore additional research is warranted. However, several days ago, a news program of Hubei TV suggested that early pregnant women infected with COVID-19 should terminate their pregnancies. This viewpoint seems oversimplified but has triggered controversy widely. In February, there were 3 pregnant women with mild COVID-19 infection in the Wuhan Central Hospital (Houhu District) who decided to terminate their pregnancy in the first trimester. Early pregnancy is a challenging and vulnerable period, and viral infection at this stage could potentially affect embryogenesis and fetal organ development, but there is still no evidence for the vertical transmission of COVID-19 so far. In February 13rd, 2020, Chen et al. reviewed nine cases of COVID-19 infected pregnant women, and reported none of their neonates had been infected through vertical transmission [[2]Chen H. Guo J. Wang C. et al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.Lancet. 2020; 395: 809-815Abstract Full Text Full Text PDF PubMed Scopus (2618) Google Scholar]. Prior to COVID-19, there were a total of six coronavirus species that induced human infection including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) which led to the outbreak of pneumonia, but no vertical transmission of the coronavirus had been confirmed [[4]Alserehi H. Wali G. Alshukairi A. et al.Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome.BMC Infect Dis. 2016; 16: 105Crossref PubMed Scopus (140) Google Scholar,[5]Munster V.J. Koopmans M. van Doremalen N. et al.A novel coronavirus emerging in China - key questions for impact assessment.N Engl J Med. 2020; 382: 692-694Crossref PubMed Scopus (934) Google Scholar]. With reference to the experience to SARS or MERS, they can cause preterm, miscarriage, stillbirth, and fetal growth restriction in pregnant women, associated with placental insufficiency, but not vertical transmission. There is no evidence that SARS-CoV or MERS-CoV itself can cause fetal malformations, because neither of them passes across the placental barrier [[3]Wong S.F. Chow K.M. Leung T.N. et al.Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome.Am J Obstet Gynecol. 2004; 191: 292-297Abstract Full Text Full Text PDF PubMed Scopus (696) Google Scholar,[4]Alserehi H. Wali G. Alshukairi A. et al.Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome.BMC Infect Dis. 2016; 16: 105Crossref PubMed Scopus (140) Google Scholar]. Children born to pregnant women infected with SARS showed similar physical and mental development when followed up to 10 months in both full-term and preterm babies. Current research on long-term health of pregnant women of SARS or MERS is not available, but we anticipate that maternal SARS-CoV-2 infection would not result in significant, long-term health risks to the offspring. Pregnant women with SARS-CoV infection have a three times higher mortality rate than non-pregnant populations. However, SARS-CoV-2 infection outcome seems to have a better prognosis than SARS-CoV infection [[5]Munster V.J. Koopmans M. van Doremalen N. et al.A novel coronavirus emerging in China - key questions for impact assessment.N Engl J Med. 2020; 382: 692-694Crossref PubMed Scopus (934) Google Scholar]. Only 7.45 % of all confirmed cases are defined as "severe" according to an announcement by National Health Commission of China on Feb 15th, 2020. Based on the limited number of cases reported, there is no evidence indicating a worse outcome of maternal patients than that of general population. On the other hand, pregnancy terminations in early pregnancy may result in post-abortion infection, which might aggravate the maternal COVID-19 illness. Therefore, consideration of termination of pregnancy has to be individualized during this COVID-19 outbreak. For pregnant patients with mild symptoms, treatment should be modified to avoid using teratogenic drugs near the fetus. Patients are commonly at higher oxygen demand during early pregnancy, so hypoxemia should be monitored, and interventions should be provided without delay. For severe patients during early pregnancy, the first priority is to ensure maternal safety. Decisions of early pregnancy termination should be considered upon risk factors including viral load, transmission generations, range of lung lesions by CT (more than two lobes), maternal age, and coexisting disorders (diabetes, cardiovascular diseases etc.). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. He-feng Huang put forward the initial ideas and opinions, which were drafted by Yan-ting Wu, Cheng Li, and Chen-jie Zhang. Not applicable. Not applicable.
The impact of COVID-19 infections on pregnancy outcomes in women

Ke Xu,Wen Sun,Shuangshuang Yang,Tianqi Liu,Ning Hou

DOI: https://doi.org/10.1186/s12884-024-06767-7

2024-08-29

Abstract:Background: Given that viral infections can increase the risk of adverse pregnancy outcomes, such as spontaneous miscarriage, preterm premature rupture of membranes, and preterm birth, the effects of COVID-19, a novel emerging coronavirus disease rapidly spreading globally, on pregnancy outcomes have garnered significant attention. Methods: We conducted a review of studies related to pregnant women infected with SARS-CoV-2 over the past five years (December 2019 to April 2023), utilizing search engines such as PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI). This study was registered with PROSPERO with ID: CRD42024540849. Results: A total of 218 articles were screened, with 15 studies meeting the inclusion criteria for this research, including 12 cohort studies, one cross-sectional study, one case-control study, and one case series. Six studies found that the preterm birth rate was higher in the infected group compared to the control group; five studies showed that the cesarean section rate was higher in the infected group; three studies found that the APGAR scores of newborns were higher in the control group than in the infected group; three studies indicated that the mortality rate of newborns in the infected group was higher than that in the control group. Conclusions: Our retrospective review suggests that compared to pregnant women not infected with SARS-CoV-2, those diagnosed with COVID-19 are more likely to experience adverse outcomes such as preterm birth, cesarean delivery, and low birth weight in newborns.
Associations of COVID-19 Pandemic with Clinical Manifestations among the Uninfected Pregnant Women in China: A Combined Cohort Study

Bin Wang,Hang An,Huanqing Hu,Wei Zhao,Bahabaike Jiangtulu,Shuo Wang,Jiamei Wang,Junxi Chen,Manman Long,Zewu Li,Yu Jin,Yuhuan Li,Huiting Chen,Tao Xue,Xiqing Li,Kexin Li,Suhong Gao,Rongwei Ye,Jiangli Di,Xiaohong Liu,Zhiwen Li

DOI: https://doi.org/10.2139/ssrn.3696856

2020-01-01

Abstract:Background: Whether coronavirus disease 2019 (COVID-19) pandemic would affect pregnancy-associated factors of uninfected pregnant women was rarely reported.Methods: A total of 32,277 pregnant women from six sites (Hubei Province, Guangdong Province, Hebei Province, Shandong Province, Yunnan Province and Beijing City) were finally recruited. We conducted a retrospective combined cohort study to analyze the associations between the number of prenatal examinations (NPE), delivery gestational week (DGW), the risk of caesarean section (CS), stillbirth, neonatal weight, preterm birth, macrosomia, small for gestational age (SGA), large for gestational age (LGA) and the COVID-19 in two time-periods, the pre-pandemic period (P-2019, 1/1/19-5/31/19) and the pandemic period (P-2020, 1/1/20-5/31/20).Findings: After adjusting for other covariates, we found the NPE, DGW, and SGA were negatively associated with the COVID-19 pandemic, whereas the CS and preterm birth rates were positively associated with the COVID-19, with adjusted relative risks (aRRs) of 1.11 [95% confidence interval (CI) 1.06–1.17] and 1.37 (95% CI: 1.02–1.84) respectively in Hubei. For Guangdong, the associations of CS and preterm birth with the COVID-19 were similar in Hubei. In contrast, limited associations were evident in other areas, except for a positive association with macrosomia [aRR = 1.26 (95% CI: 1.03–1.55)] in Beijing.Interpretation: The CS and preterm birth rates increased slightly in areas that were more affected by the pandemic than other areas among uninfected pregnant women. NPEs were not significantly interrupted and most maternal and neonatal clinical characteristics were within the normal ranges.Funding: National Key Research and Development Program, National Natural Science Foundation of China and National Health Commission Capacity Building and Continuing Education Center.Declaration of Interests: All authors declare to have no conflict of interest.Ethics Approval Statement: The study was approved by the Peking University ethics board (no. IRB00001052-20025).
Outcomes of SARS‐CoV‐2 infection in early pregnancy—A systematic review and meta‐analysis

Kenny A. Rodriguez‐Wallberg,Hanna P. Nilsson,Emelie Bergman Røthe,Allan Zhao,Prakesh S. Shah,Ganesh Acharya

DOI: https://doi.org/10.1111/aogs.14764

2024-01-11

Acta Obstetricia Et Gynecologica Scandinavica

Abstract:As there is limited information on the association between SARS‐CoV‐2 infection in early pregnancy and outcomes thereof, we aimed to systematically review the maternal, fetal, and neonatal outcomes following SARS‐CoV‐2 infection in early pregnancy, defined as <20 weeks of gestation. A total of 18 studies, 12 retrospective and six prospective, were included in this review, reporting on 10 147 SARS‐CoV‐2‐positive women infected in early pregnancy, 9533 neonates, and 180 882 SARS‐CoV‐2 negative women. In this comprehensive systematic review of available evidence, we identified no statistically significant adverse association between SARS‐CoV‐2 infection in early pregnancy (before 20 weeks of gestation) and fetal, neonatal, or maternal outcomes. However, a 44% increase in miscarriage rate is concerning and further studies of larger sample size are needed to confirm or refute our findings. Introduction Available data on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and pregnancy outcomes mostly refer to women contracting the infection during advanced pregnancy or close to delivery. There is limited information on the association between SARS‐CoV‐2 infection in early pregnancy and outcomes thereof. Material and methods We aimed to systematically review the maternal, fetal and neonatal outcomes following SARS‐CoV‐2 infection in early pregnancy, defined as <20 weeks of gestation (PROSPERO Registration 2020 CRD42020177673). Searches were carried out in PubMed, Medline, EMBASE, and Scopus databases from January 2020 until April 2023 and the WHO database of publications on coronavirus disease 2019 (COVID‐19) from December 2019 to April 2023. Cohort and case–control studies on COVID‐19 occurring in early pregnancy that reported data on maternal, fetal, and neonatal outcomes were included. Case reports and studies reporting only exposure to SARS‐CoV‐2 or not stratifying outcomes based on gestational age were excluded. Data were extracted in duplicate. Meta‐analyses were conducted when appropriate, using R meta (R version 4.0.5). Results A total of 18 studies, 12 retrospective and six prospective, were included in this review, reporting on 10 147 SARS‐CoV‐2‐positive women infected in early pregnancy, 9533 neonates, and 180 882 SARS‐CoV‐2 negative women. The studies had low to moderate risk of bias according to the Newcastle–Ottawa quality assessment Scale. The studies showed significant clinical and methodological heterogeneity. A meta‐analysis could be performed only on the outcome miscarriage rate, with a pooled random effect odds ratio of 1.44 (95% confidence interval 0.96–2.18), showing no statistical difference in miscarriage in SARS‐CoV‐2‐infected women. Individual studies reported increased incidences of stillbirth, low birthweight and preterm birth among neonates born to mothers affected by COVID‐19 in early pregnancy; however, these results were not consistent among all studies. Conclusions In this comprehensive systematic review of available evidence, we identified no statistically significant adverse association between SARS‐CoV‐2 infection in early pregnancy (before 20 weeks of gestation) and fetal, neonatal, or maternal outcomes. However, a 44% increase in miscarriage rate is concerning and further studies of larger sample size are needed to confirm or refute our findings.

obstetrics & gynecology
Maternal SARS-COV-2 infection and prematurity: the Southern Michigan COVID-19 collaborative

Ray Bahado-Singh,Adi L. Tarca,Yasmin G. Hasbini,Robert J. Sokol,Madhurima Keerthy,Gregory Goyert,Theodore Jones,Lisa Thiel,Pooja Green,Youssef Youssef,Courtney Townsel,Shyla Vengalil,Paige Paladino,Amy Wright,Mariam Ayyash,Gayathri Vadlamud,Marta Szymanska,Sonia Sajja,Onur Turkoglu,Grace Sterenberg,Alexandra R. Mangus,Micheal Baracy,Maria Gibbons,Karlee Grace,Kaitlyn Houston,Jessica Norman,Dereje W. Gudicha,Sonia S. Hassan,For The Southern Michigan Regional COVID-19 Collaborative

DOI: https://doi.org/10.1080/14767058.2023.2199343

2023-05-24

Abstract:COVID-19 has been reported to increase the risk of prematurity, however, due to the frequent absence of unaffected controls as well as inadequate accounting for confounders in many studies, the question requires further investigation. We sought to determine the impact of COVID-19 disease on preterm birth (PTB) overall, as well as related subcategories such as early prematurity, spontaneous, medically indicated preterm birth, and preterm labor (PTL). We assessed the impact of confounders such as COVID-19 risk factors, a-priori risk factors for PTB, symptomatology, and disease severity on rates of prematurity. This was a retrospective cohort study of pregnant women from March 2020 till October 1st, 2020. The study included patients from 14 obstetric centers in Michigan, USA. Cases were defined as women diagnosed with COVID-19 at any point during their pregnancy. Cases were matched with uninfected women who delivered in the same unit, within 30 d of the delivery of the index case. Outcomes of interest were frequencies of prematurity overall and subcategories of preterm birth (early, spontaneous/medically indicated, preterm labor, and premature preterm rupture of membranes) in cases compared to controls. The impact of modifiers of these outcomes was documented with extensive control for potential confounders. A p value <.05 was used to infer significance. The rate of prematurity was 8.9% in controls, 9.4% in asymptomatic cases, 26.5% in symptomatic COVID-19 cases, and 58.8% among cases admitted to the ICU. Gestational age at delivery was noted to decrease with disease severity. Cases were at an increased risk of prematurity overall [adjusted relative risk (aRR) = 1.62 (1.2–2.18)] and of early prematurity (<34 weeks) [aRR = 1.8 (1.02–3.16)] when compared to controls. Medically indicated prematurity related to preeclampsia [aRR = 2.46 (1.47–4.12)] or other indications [aRR = 2.32 (1.12–4.79)], were the primary drivers of overall prematurity risk. Symptomatic cases were at an increased risk of preterm labor [aRR = 1.74 (1.04–2.8)] and spontaneous preterm birth due to premature preterm rupture of membranes [aRR = 2.2(1.05–4.55)] when compared to controls and asymptomatic cases combined. The gestational age at delivery followed a dose-response relation with disease severity, as more severe cases tended to deliver earlier (Wilcoxon p < .05). COVID-19 is an independent risk factor for preterm birth. The increased preterm birth rate in COVID-19 was primarily driven by medically indicated delivery, with preeclampsia as the principal risk factor. Symptomatic status and disease severity were significant drivers of preterm birth.

obstetrics & gynecology
#49: Management and Outcomes of Infants Born to Mothers with SARS-CoV-2 Infection in Pregnancy

Sebastian Otero,Allaa Fadl-Alla,Malika D Shah,Allison Sakowicz,Chiedza Mupanomunda,Elisheva D Shanes,Jeffery A Goldstein,Emily S Miller,Leena B Mithal

DOI: https://doi.org/10.1093/jpids/piab031.033

2021-06-01

Journal of the Pediatric Infectious Diseases Society

Abstract:Abstract Background SARS-CoV-2 infections during pregnancy continue in this ongoing pandemic. Care of mother-infant dyads affected by SARS-CoV-2 infection in pregnancy has evolved. Perinatal viral transmission is rare. However, there remain few detailed reports on characteristics and management of these infants during neonatal hospitalization. Our objective was to investigate management and outcomes of infants born to women with laboratory-confirmed SARS-CoV-2 infection in pregnancy including resuscitation, NICU care, separation, and breastfeeding. Methods This is a study of mother-infant dyads with SARS-CoV-2 in pregnancy at Prentice Women’s Hospital in Chicago, IL (3/2020-11/2020). Dyads were tracked prospectively with data obtained by review of electronic medical records including demographics, maternal clinical history, COVID symptoms, and neonatal course. Women were universally screened with SARS-CoV-2 PCR at admission. Mothers were categorized as 1) acute infection (-14–0 days from delivery) vs. previous infection (>14 days), and 2) symptomatic vs. asymptomatic (defined by CDC criteria). Infants of mothers with acute infection were tested for SARS-CoV-2. Results We report a diverse cohort of 210 women with SARS-CoV-2 in pregnancy, 114 acute and 96 previous infection (range 0–229 days between positive PCR and delivery) [Table 1]. Over half (56%) of women were symptomatic, 29/114 (25%) with acute infection, 89/96 (93%) with previous infection. Of 211 infants, one asymptomatic infant tested positive for SARS-CoV-2. The overall rate of preterm birth was 10.9% in this cohort. The rate of preterm birth was 26.6% (8/30) in the symptomatic acute infection group (p=0.055) and birthweight was significantly lower (p=0.03). There was no apparent increased need for resuscitation at delivery. APGARs were 8 (8–9) and 9 (8–9) at 1 and 5 minutes, respectively. Six percent of infants >35 weeks had respiratory distress. About 7% had failed hearing screen (historic Prentice rate ~4%). Separation of infants from mothers with acute infection decreased over time due to policy changes based on available safety data for rooming in (Cuzick’s test for trend p<0.001). Most infants (75%) received breastmilk in the hospital over this timeframe; this was low initially and increased over this timeframe (p<0.001). For example, 45% of mothers with acute infection provided breastmilk in May compared to nearly 100% in November. Twelve women were diagnosed with chorioamnionitis due to fever in labor and also had acute SARS-CoV-2 infection. Conclusion Infants of mothers with SARS-CoV-2 in pregnancy had favorable short-term outcomes, with decrease in separation and increase in breastfeeding over this timeframe. Complex factors likely contribute to differences in birthweight and prematurity in the acute symptomatic group. Isolated fever in the setting of acute SARS-CoV-2 presents a dilemma regarding maternal chorioamnionitis, resulting in antibiotic exposure. Longitudinal follow-up is needed to determine infant outcomes (true hearing loss, development) following maternal SARS-CoV-2 infection.

pediatrics,infectious diseases
A retrospective observational study on maternal and neonatal outcomes of COVID-19: Does the mild SARS-CoV-2 infection affect the outcome?

Jing Li,Xiang Li,Peiying Ye,Yun You,Yu Wang,Jing Zhang,Weihua Zhao,Zhiying Yu,Runsi Yao,Jie Tang

DOI: https://doi.org/10.7717/peerj.16651

IF: 3.061

2023-12-14

PeerJ

Abstract:Background Currently, several SARS-CoV-2 variants, including Omicron, are still circulating globally. This underscores the necessity for a comprehensive understanding of their impact on obstetric and neonatal outcomes in pregnant women, even in cases of mild infection. Methods We conducted a retrospective, single-center observational study to investigate the association between gestational SARS-CoV-2 infection and maternal-fetal outcomes in the Chinese population. The study enrolled 311 pregnant patients with SARS-CoV-2 infection (exposure group) and 205 uninfected pregnant patients (control group). We scrutinized the hospital records to collect data on demographics, clinical characteristics, and maternal and neonatal outcomes for subsequently comparison. Results Similar characteristics were observed in both groups, including maternal age, height, BMI, gravidity, parity, and comorbidities ( p > 0.05). A majority (97.4%) of pregnant women in the exposure group with COVID-19 experienced mild clinical symptoms, with fever (86.5%) and cough (74.3%) as the primary symptoms. The exposure group exhibited significantly higher incidences of cesarean section and fetal distress compared to the control group ( p < 0.05). Furthermore, pregnant women in the exposure group showed reduced levels of hemoglobin and high-sensitivity C-reactive protein, while experiencing significantly increased levels of lymphocytes, prothrombin time, alanine aminotransferase, and aspartate aminotransferase ( p < 0.05). Notably, recent SARS-CoV-2 infection prior to delivery appeared to have an adverse impact on liver function, blood and coagulation levels in pregnant women. When comparing the two groups, there were no significant differences in the postpartum hemorrhage rate, premature birth rate, birth weight, neonatal asphyxia rate, neonatal department transfer rate, and neonatal pneumonia incidence. Conclusions Our study suggests that mild COVID-19 infection during pregnancy does not have detrimental effects on maternal and neonatal outcomes. However, the increased risks of events such as fetal distress and cesarean section, coupled with potential alterations in physical function, reveal the consequences of SARS-CoV-2 infection during pregnancy, even in mild cases. These findings emphasize the importance of proactive management and monitoring of pregnant individuals with COVID-19.

multidisciplinary sciences
Maternal and neonatal outcomes and clinical laboratory testing of pregnant women with COVID-19 during the BA.5.2/BF.7 surge

Jiali Cao,Zehong Huang,Jing Zeng,Jumei Liu,Weilun Zuo,Zhiying Su,Yujuan Chen,Weiwei Yu,Huiming Ye

DOI: https://doi.org/10.1080/21505594.2024.2360130

IF: 5.428

2024-06-05

Virulence

Abstract:The impact of COVID-19 on pregnant women and newborns continues to be a critical societal concern. However, the majority of research focuses on the disease resulting from the early pandemic variants, without sufficient study on the more recent BA.5.2/BF.7. We retrospectively recruited pregnant women giving birth during the surge of the BA.5.2/BF.7 and analysed the risk impact of COVID-19 on maternal and neonatal outcomes. Furthermore, subjects matched through propensity scores were used for the analysis of clinical laboratory tests. A total of 818 pregnant women were enrolled, among 276 (33.7%) were diagnosed with SARS-CoV-2 during childbirth. COVID-19 significantly increased the risk of a hospital length of stay equal to or greater than seven days and neonatal admission to the neonatal intensive care unit, with an aHR of 2.03 (95% CI, 1.22–3.38) and 1.51 (95% CI, 1.12–2.03), respectively. In the analysis of 462 matched subjects, it was found that subjects infected with SARS-CoV-2 tended slight leucopenia and coagulation abnormalities. We found that during the surge of the BA.5.2/BF.7, COVID-19 increased the risk of maternal and neonatal outcomes among Chinese pregnant women. This finding offers significant insights to guide clinical practices involving pregnant women infected with the recently emerged Omicron subvariants.

microbiology,immunology,infectious diseases
Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review

Mohaimenul Islam,Tahmina Nasrin Poly,Bruno Andreas Walther,Hsuan Chia Yang,Cheng-Wei Wang,Wen-Shyang Hsieh,Suleman Atique,Hosna Salmani,Belal Alsinglawi,Ming Ching Lin,Wen Shan Jian,Yu-Chuan Jack Li,Md. Mohaimenul Islam

DOI: https://doi.org/10.3389/fmed.2020.573468

IF: 3.9

2020-12-03

Frontiers in Medicine

Abstract:Background and Objective: Coronavirus disease 2019 (COVID-19) characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created serious concerns about its potential adverse effects. There are limited data on clinical, radiological, and neonatal outcomes of pregnant women with COVID-19 pneumonia. This study aimed to assess clinical manifestations and neonatal outcomes of pregnant women with COVID-19. Methods: We conducted a systematic article search of PubMed, EMBASE, Scopus, Google Scholar, and Web of Science for studies that discussed pregnant patients with confirmed COVID-19 between January 1, 2020, and April 20, 2020, with no restriction on language. Articles were independently evaluated by two expert authors. We included all retrospective studies that reported the clinical features and outcomes of pregnant patients with COVID-19. Results: Forty-seven articles were assessed for eligibility; 13 articles met the inclusion criteria for the systematic review. Data is reported for 235 pregnant women with COVID-19. The age range of patients was 25–40 years, and the gestational age ranged from 8 to 40 weeks plus 6 days. Clinical characteristics were fever [138/235 (58.72%)], cough [111/235 (47.23%)], and sore throat [21/235 (8.93%)]. One hundred fifty six out of 235 (66.38%) pregnant women had cesarean section, and 79 (33.62%) had a vaginal delivery. All the patients showed lung abnormalities in CT scan images, and none of the patients died. Neutrophil cell count, C-reactive protein (CRP) concentration, ALT, and AST were increased but lymphocyte count and albumin levels were decreased. Amniotic fluid, neonatal throat swab, and breastmilk samples were taken to test for SARS-CoV-2 but all found negativ results. Recent published evidence showed the possibility of vertical transmission up to 30%, and neonatal death up to 2.5%. Pre-eclampsia, fetal distress, PROM, pre-mature delivery were the major complications of pregnant women with COVID-19. Conclusions: Our study findings show that the clinical, laboratory and radiological characteristics of pregnant women with COVID-19 were similar to those of the general populations. The possibility of vertical transmission cannot be ignored but C-section should not be routinely recommended anymore according to latest evidences and, in any case, decisions should be taken after proper discussion with the family. Future studies are needed to confirm or refute these findings with a larger number of sample sizes and a long-term follow-up period.

medicine, general & internal
Ethical Evaluation of “Retainer Fee” Medical Practice

M. H. Needell,J. Kenyon

DOI: https://doi.org/10.1086/JCE200516108

2005-03-01

Abstract:This article examines the reasons that some physicians have recently opted to reduce the size of their practice rosters to allow more time for each patient in exchange for a retainer fee from patients. These physicians also offer supplementary, nonmedical amenities to patients as part of their service. Because physicians have reduced the size of their practice rosters and have increased the price tag for their services, some patients have lost access to their care. We have tried to assess the ethical propriety of such a change in the design of medical practices by weighing plausible, ethically relevant arguments favoring and opposing RFMP. Physicians are ethically obligated first and foremost to promote and protect the health of their patients. RFMP fulfills this duty directly by ensuring prompt and ample professional time for the care of patients. It does so indirectly by allowing time for physicians' continuing education, which in turn should upgrade the quality of care. It also advances the ethical goals of autonomy as it allows patients to choose their own physicians and to spend their money as they please. On the other hand, these ethical positives are offset by the cost of retainer fees that may exclude access of patients to their physicians' care. Even if ethical tradition obligates physicians primarily to patients under their specific care, as professionals and as private citizens, they also have a responsibility to support the health of the entire community. RFMP does little to advance this cause, except that by optimizing the conditions under which their own private patients receive healthcare, they call attention to shortcomings in prevailing public healthcare policies, which by comparison fall short of that standard. An assumption that health is not properly a market commodity, and that all people should receive healthcare on equal terms, would expose RFMP to moral reproof. From an ethical perspective, we find sufficient cause for concern and caution in this innovative style of practice. Nevertheless, the weight of arguments presented here does not seem to justify unequivocal moral condemnation of RFMP. As neither pro nor con views seem to have settled the ethical question, definitive moral judgment on RFMP will probably depend on the outcome of future experience and ongoing evaluation. The implications of RFMP for any future healthcare system are not clear, at least to us.
Pregnancy and postpartum outcomes in a universally tested population for SARS‐CoV‐2 in New York City: a prospective cohort study

M Prabhu,K Cagino,KC Matthews,RL Friedlander,SM Glynn,JM Kubiak,YJ Yang,Z Zhao,RN Baergen,JI DiPace,AS Razavi,DW Skupski,JR Snyder,HK Singh,RB Kalish,CM Oxford,LE Riley

DOI: https://doi.org/10.1111/1471-0528.16403

2020-08-13

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To describe differences in outcomes between pregnant women with and without COVID‐19</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Design</h3><p>Prospective cohort study of pregnant women consecutively admitted for delivery, and universally tested via nasopharyngeal (NP) swab for SARS‐CoV‐2 using reverse transcriptase polymerase chain reaction (RT‐PCR). All infants of mothers with COVID‐19 underwent SARS‐CoV‐2 testing.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Setting</h3><p>Three New York City hospitals</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Population</h3><p>Pregnant women > 20 weeks' gestation admitted for delivery</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Data were stratified by SARS‐CoV‐2 result and symptomatic status, and summarized using parametric and nonparametric tests.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Main Outcome Measures</h3><p>Prevalence and outcomes of maternal COVID‐19; obstetric outcomes; neonatal SARS‐CoV‐2; placental pathology.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of 675 women admitted for delivery, 10.4% were positive for SARS‐CoV‐2, of whom 78.6% were asymptomatic. We observed differences in sociodemographics and comorbidities between women with symptomatic vs. asymptomatic vs. no COVID‐19. Cesarean delivery rates were 46.7% in symptomatic COVID‐19, 45.5% in asymptomatic COVID‐19, and 30.9% without COVID‐19 (p=0.044). Postpartum complications (fever, hypoxia, readmission) occurred in 12.9% of women with COVID‐19 vs 4.5% of women without COVID‐19 (p<0.001). No woman required mechanical ventilation, and no maternal deaths occurred. Among 71 infants tested, none were positive for SARS‐CoV‐2. Placental pathology demonstrated increased frequency of fetal vascular malperfusion, indicative of thrombi in fetal vessels, in women with vs. without COVID‐19 (48.3% vs 11.3%, <i>p </i> <0.001). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Among pregnant women with COVID‐19 at delivery, we observed increased cesarean delivery rates and increased frequency of maternal complications in the postpartum period. Additionally, intraplacental thrombi may have maternal and fetal implications for COVID‐19 infections remote from delivery.</p></section>
Maternal and Neonatal Outcomes During the COVID-19 Infection in China: Data from a Retrospective Cohort Study

Yingying Lin,Zhiwei Chen,Zhiwei Wu,Yongjin Xie,Li Xie,Xiaoyan Xiu

DOI: https://doi.org/10.31083/j.ceog5104095

2024-01-01

Clinical and Experimental Obstetrics & Gynecology

Abstract:Background: This study aimed to investigate the relationship between coronavirus disease 2019 (COVID-19) disease and maternal and neonatal outcomes. Methods: This is a retrospective cohort study. This study analyzed 3615 participants from Fujian Provincial Maternity and Child Health Hospital Fujian Obstetrics and Gynecology Hospital from November 1, 2022, to January 31, 2023. All pregnant women must provide a 24-hour nucleic acid test report when they are admitted to the hospital to deliver babies. Chi-square test and linear regression analyses were used to evaluate the risk of COVID-19 infection with the maternal outcome and neonatal outcomes. Results: Finally, 3615 patients were included in the cohort study. 549 (15.2%) were diagnosed with COVID-19 infection. The most common symptom is fever, cough, sore throat. 51 (9.2%) newborns had positive test results. In addition, the mother with COVID-19 infection were significantly associated with a higher rate of premature rupture of membranes (PPROM) and postpartum hemorrhage. Furthermore, a mother with COVID-19 infection was significantly associated with a higher rate of low birth weight infant (LBW) and macrosomia in newborns, higher rate of respiratory distress syndrome (RDS), higher rate of intro-ventricular hemorrhage (IVH), higher rate of neonatal pneumonia, and a higher rate of aspiration of amniotic fluid and meconium syndrome (AAFMS) (all p < 0.05). Conclusions: This study proves that COVID-19 infection is a potential risk factor for adverse pregnancy outcomes. The COVID-19 epidemic continues, requiring targeted public health measures to reduce the infection rate in pregnant women and the poor prognosis of mothers and children.
A prospective cohort study of pregnancy outcomes following antepartum infection with SARS-CoV-2

James D Doss,Emily Diveley,Fan Zhang,Amy Scheffer,Ruizhi Huang,Daniel Jackson,Nandini Raghuraman,Ebony B Carter,Indira U Mysorekar,Jeannie C Kelly

DOI: https://doi.org/10.1016/j.preghy.2024.101152

2024-08-29

Abstract:Objectives: Our study aimed to explore the impact of COVID-19 infection on pregnancy outcomes, accounting for the progression of variants, vaccines, and treatment modalities. Study design: We performed a prospective longitudinal cohort study at two urban tertiary centers enrolling patients with a confirmed intrauterine singleton pregnancy from December 23, 2020 to July 18, 2022. Patients were evaluated for SARS-CoV-2 infection at enrollment and every trimester using serum antibody testing. The primary outcome was preterm birth. Symptom and treatment data were collected from pregnant patients with COVID-19 infections. Variant strain infection status was determined from local wastewater analysis. Results: 448 patients were enrolled, and 390 patients were retained through delivery with 159 unexposed and 231 exposed patients, of whom 56 patients (26.0 %) crossed over after enrollment to the exposed cohorts during pregnancy. There was no difference in rates of preterm birth between exposed and unexposed cohorts (14.6 % vs 11.3 %), in deliveries < 34 weeks (1.5 % vs 2.7 %), PPROM, (0.4 % vs 1.3 %), or gestational age at delivery (38.1 vs 38.2). Exposed patients were significantly more likely to be diagnosed with a hypertensive disorder (aOR 2.3, 95 % CI 1.2-4.1), specifically gestational hypertension (aOR 2.8, 95 % CI 1.3--6.0), but not preeclampsia/eclampsia. There were no differences in individual or composite neonatal outcomes. Conclusions: Our study contributed to the understanding of the effects of SARS-CoV-2 infection on pregnancy outcomes, with increased risk of hypertensive disorders of pregnancy but overall, no differences in adverse neonatal outcomes. Regular antenatal PCR and antibody screening allowed for higher detection and inclusion of patients with asymptomatic SARS-CoV-2 infection and effects on maternal and neonatal outcomes.

Pharmacoepidemiology as a focus for clinical epidemiology in developing countries.

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021

Mucosal Allergic Sensitization to Cockroach Allergens Is Dependent on Proteinase Activity and Proteinase-Activated Receptor-2 Activation

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

An Analysis of the CRONOS Register Study

Rheumatic Disease Clinics of North America. Vitamin D. Preface.

Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China

Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review

Is Termination of Early Pregnancy Indicated in Women with COVID-19?

The impact of COVID-19 infections on pregnancy outcomes in women

Associations of COVID-19 Pandemic with Clinical Manifestations among the Uninfected Pregnant Women in China: A Combined Cohort Study

Outcomes of SARS‐CoV‐2 infection in early pregnancy—A systematic review and meta‐analysis

Maternal SARS-COV-2 infection and prematurity: the Southern Michigan COVID-19 collaborative

#49: Management and Outcomes of Infants Born to Mothers with SARS-CoV-2 Infection in Pregnancy

A retrospective observational study on maternal and neonatal outcomes of COVID-19: Does the mild SARS-CoV-2 infection affect the outcome?

Maternal and neonatal outcomes and clinical laboratory testing of pregnant women with COVID-19 during the BA.5.2/BF.7 surge

Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review

Ethical Evaluation of “Retainer Fee” Medical Practice

Pregnancy and postpartum outcomes in a universally tested population for SARS‐CoV‐2 in New York City: a prospective cohort study

Maternal and Neonatal Outcomes During the COVID-19 Infection in China: Data from a Retrospective Cohort Study

A prospective cohort study of pregnancy outcomes following antepartum infection with SARS-CoV-2